Cullinan Therapeutics Inc
CGEM
Market Cap$445.42M
Close$
$1.50
78.5% downside
Current Fair Value
78.5% downsideOvervalued by 78.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $445.42 Million |
|---|---|
| Enterprise Value | $374.24 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.11 |
| Beta | -0.07 |
| Outstanding Shares | 59,015,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.15 |
|---|---|
| PEG | -3.23 |
| Price to Sales | - |
| Price to Book Ratio | 0.87 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.59 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Cullinan Oncology Inc
24 employeesCullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company¡¯s strategy is to build a pi...